Next Article in Journal
Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets
Next Article in Special Issue
Semaphorin 3C and Its Receptors in Cancer and Cancer Stem-Like Cells
Previous Article in Journal
The Repertoire of Adenovirus in Human Disease: The Innocuous to the Deadly
Previous Article in Special Issue
Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Biomedicines 2018, 6(1), 31; https://doi.org/10.3390/biomedicines6010031

CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance

1
Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
2
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 2 February 2018 / Revised: 28 February 2018 / Accepted: 5 March 2018 / Published: 8 March 2018
(This article belongs to the Special Issue Stem Cells and Cancer Therapeutics)
Full-Text   |   PDF [1413 KB, uploaded 8 March 2018]   |  

Abstract

Metastasis is the primary cause of cancer patient morbidity and mortality, but due to persisting gaps in our knowledge, it remains untreatable. Metastases often occur as patient tumors progress or recur after initial therapy. Tumor recurrence at the primary site may be driven by a cancer stem-like cell or tumor progenitor cell, while recurrence at a secondary site is driven by metastatic cancer stem cells or metastasis-initiating cells. Ongoing efforts are aimed at identifying and characterizing these stem-like cells driving recurrence and metastasis. One potential marker for the cancer stem-like cell subpopulation is CD117/c-kit, a tyrosine kinase receptor associated with cancer progression and normal stem cell maintenance. Further, activation of CD117 by its ligand stem cell factor (SCF; kit ligand) in the progenitor cell niche stimulates several signaling pathways driving proliferation, survival, and migration. This review examines evidence that the SCF/CD117 signaling axis may contribute to the control of cancer progression through the regulation of stemness and resistance to tyrosine kinase inhibitors. View Full-Text
Keywords: CD117/c-kit; cancer progression; cancer stem cell; tumor-initiating cell; metastasis; tyrosine kinase inhibitor; stem cell factor CD117/c-kit; cancer progression; cancer stem cell; tumor-initiating cell; metastasis; tyrosine kinase inhibitor; stem cell factor
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Foster, B.M.; Zaidi, D.; Young, T.R.; Mobley, M.E.; Kerr, B.A. CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance. Biomedicines 2018, 6, 31.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top